Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The neurobiological basis of cognitive side effects of electroconvulsive therapy, a systematic review

  • Bassa, Adriana
  • Sagués, Teresa
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Serra, Pilar
  • Martínez Amorós, Erika|||0000-0002-6718-7346
  • Palao, Diego|||0000-0002-3323-6568
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
Decades of research have consistently demonstrated the efficacy of electroconvulsive therapy (ECT) for the treatment of major depressive disorder (MDD), but its clinical use remains somewhat restricted because of its cognitive side effects. The aim of this systematic review is to comprehensively summarize current evidence assessing potential biomarkers of ECT-related cognitive side effects. Based on our systematic search of human studies indexed in PubMed, Scopus, and Web of Knowledge, a total of 29 studies evaluating patients with MDD undergoing ECT were reviewed. Molecular biomarkers studies did not consistently identify concentration changes in plasma S-100 protein, neuron-specific enolase (NSE), or Aβ peptides significantly associated with cognitive performance after ECT. Importantly, these findings suggest that ECT-related cognitive side effects cannot be explained by mechanisms of neural cell damage. Notwithstanding, S-100b protein and Aβ40 peptide concentrations, as well as brain-derived neurotrophic factor (BDNF) polymorphisms, have been suggested as potential predictive biomarkers of cognitive dysfunction after ECT. In addition, recent advances in brain imaging have allowed us to identify ECT-induced volumetric and functional changes in several brain structures closely related to memory performance such as the hippocampus. We provide a preliminary framework to further evaluate neurobiological cognitive vulnerability profiles of patients with MDD treated with ECT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Histone Modifications and Their Targeting in Lymphoid Malignancies

  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Winkler, René|||0000-0002-7570-0242
  • Santos, Juliana|||0000-0003-4148-9570
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Roué, Gaël|||0000-0003-0245-2257
In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Manero-Rupérez, Noemí
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Soler Castany, Marta
  • Ros-Blanco, Lia
  • Navarro, Pilar|||0000-0003-4314-4584
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genome-Wide Studies in Ischaemic Stroke, Are Genetics Only Useful for Finding Genes?

  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Cullell, Natalia|||0000-0001-5118-1014
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Ischaemic stroke is a complex disease with some degree of heritability. This means that heritability factors, such as genetics, could be risk factors for ischaemic stroke. The era of genome-wide studies has revealed some of these heritable risk factors, although the data generated by these studies may also be useful in other disciplines. Analysis of these data can be used to understand the biological mechanisms associated with stroke risk and stroke outcome, to determine the causality between stroke and other diseases without the need for expensive clinical trials, or to find potential drug targets with higher success rates than other strategies. In this review we will discuss several of the most relevant studies regarding the genetics of ischaemic stroke and the potential use of the data generated.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.